Psychedelics manufacturer Psygen has received the dealer’s license for LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline.
Receipt of the Health Canada dealers licence opens the doors to the commercial production of psychedelics at Psygen’s Good Manufacturing Practices (GMP) facility.
The licence will enable, Psygen Labs, a wholly-owned subsidiary of Psygen, to manufacture, sell, import, export and otherwise deal with the above-listed controlled substances. The company In also manufactures high-potential unscheduled substances such as 5-MeO-DMT, ibogaine and others.
CEO of Psygen, Danny Motyka, commented: “Psygen’s dealer’s licence is a major milestone that opens the doors to commercial production of GMP psilocybin and other psychedelics at our facility.
“Our dealer’s licence issued following a perfect inspection, meaning we had zero observations from the inspector, which is indicative of the diligence and skill that Psygen brings to our work.”
The licence will enable a global reach for Psygen’s facility, which is Canada’s only dedicated manufacturer of synthetic psychedelics based in Calgary, Alberta. Upon completion of the facility Psygen will begin onsite manufacturing of synthetic psychedelics for use in clinical and scientific research.
CSO, Peter van der Heyden, commented: “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.
“After two years of a global pandemic, mental health conditions are a more urgent need than ever. We are excited to supply material for use in clinical trials and the SAP to further validate the utility of psychedelic medicines.”
The company has also announced it will be providing GMP psilocybin for use in patients through Canada’s Special Access Program, following recent amendments that were made to allow access to restricted drugs such as psilocybin and MDMA through the SAP.
GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products.
The company also has over twenty supply agreements in place for psilocybin, DMT, ibogaine, 5-MeO-DMT, MDMA and LSD to be fulfilled globally.
[activecampaign form=52]
